Regeneus would like to wish everyone a Merry Christmas and
a Happy and Prosperous New Year
The Regeneus office will be closed from December 20 and will reopen on January 5
Improving quality of life through innovative cellular therapies
Regeneus is excited to announce that over 450 patients have now been commercially treated with our HiQCell® stem cell therapy. These patients are captured within our Patient Joint Registry which allows us to continue to capture long-term data so that we can learn more of the treatment effects of HiQCell.
At Regeneus, we focus on improving quality of life through cellular therapies.
We develop and commercialise proprietary technologies for the preparation of autologous point-of-care and off-the-shelf cell therapies for the treatment of musculoskeletal and other inflammatory conditions in humans and animals.